Accolade (NASDAQ:ACCD) Posts Quarterly Earnings Results

Accolade (NASDAQ:ACCD) issued its earnings results on Thursday. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01, Briefing.com reports. The company had revenue of $124.80 million for the quarter, compared to analyst estimates of $123.91 million. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.57%. The business’s revenue was up 26.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.42) EPS. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Trading Down 14.1 %

Shares of NASDAQ:ACCD traded down $1.30 during trading on Friday, reaching $7.89. 1,491,193 shares of the stock were exchanged, compared to its average volume of 585,879. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35. Accolade has a 12-month low of $6.33 and a 12-month high of $17.00. The firm has a market cap of $610.76 million, a price-to-earnings ratio of -5.93 and a beta of 2.08. The firm’s 50-day moving average price is $9.66 and its 200 day moving average price is $9.91.

Analyst Ratings Changes

ACCD has been the topic of several research analyst reports. Barclays decreased their target price on shares of Accolade from $13.00 to $11.00 and set an “equal weight” rating on the stock in a research report on Friday. Wells Fargo & Company boosted their target price on shares of Accolade from $10.00 to $12.00 and gave the stock an “equal weight” rating in a research report on Tuesday, January 9th. Truist Financial cut their price target on Accolade from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Leerink Partnrs reaffirmed an “outperform” rating on shares of Accolade in a research note on Monday, February 26th. Finally, Raymond James lifted their price target on Accolade from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 9th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Accolade presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.80.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.